Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F19%3AW0000016" target="_blank" >RIV/00064211:_____/19:W0000016 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/19:10394841
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1610381" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1610381</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14712598.2019.1610381" target="_blank" >10.1080/14712598.2019.1610381</a>
Alternative languages
Result language
angličtina
Original language name
Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
Original language description
Introduction: The expiry of patents for biologics has led to the introduction of biosimilars for the treatment of immune-mediated inflammatory diseases (IMIDs). These treatment alternatives may allow earlier and wider access to appropriate therapy for patients without increasing the economic burden on health-care systems. Prescription of biosimilars to treatment-naive patients is well accepted; however, additional considerations must be taken into account when switching clinically stable patients from reference products to biosimilars. Area covered: We discuss the current considerations related to switching from reference products to biosimilars from a physician and patient perspective. We review the clinical data and real-life experience on switching patients with IMIDs, present the position of the relevant medical societies, and discuss the importance of patient-physician communication and need for shared decision-making. Expert opinion: The introduction of biosimilars provides an opportunity to expand access to treatment for patients with IMIDs across Europe and support the financial sustainability of health-care systems. We anticipate that as the real-world evidence base grows, confirming the results of clinical trials, there will be a corresponding increase in physician and patient acceptance, not only to initiating treatment with a biosimilar, but also to switching medication from a reference product to a biosimilar.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EXPERT OPINION ON BIOLOGICAL THERAPY
ISSN
1471-2598
e-ISSN
1744-7682
Volume of the periodical
19
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
14
Pages from-to
1001-1014
UT code for WoS article
000470405400001
EID of the result in the Scopus database
2-s2.0-85072746565